Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Captopril. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 7/20 | 0.97 |
| ▸ | REN | P00797 | 4/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.97 |
| ▸ | F2 | P00734 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | LTA4H | P09960 | 1/20 | 0.97 |
| ▸ | MAPT | P10636 | 1/20 | 0.97 |
| ▸ | PEPD | P12955 | 1/20 | 0.97 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.97 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.97 |
| ▸ | HTR2A | P28223 | 1/20 | 0.97 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.97 |
| ▸ | HRH1 | P35367 | 1/20 | 0.97 |
| ▸ | THPO | P40225 | 1/20 | 0.97 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.97 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.97 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| D-Captopril SCHEMBL28209054 | 1.00 | ACE (0.97) | ACERENKDM4EF2LMNA | |
| Captopril SCHEMBL7525123 | 1.00 | ACE (0.97) | ACERENKDM4EF2LMNA | |
| D-Captopril SCHEMBL1913521 | 0.98 | ACE (1.00) | ACERENKDM4EF2LMNA | |
| D-Captopril SCHEMBL7983782 | 0.98 | ACE (1.00) | ACERENKDM4EF2LMNA | |
| D-Captopril SCHEMBL678794 | 0.98 | ACE (1.00) | ACERENKDM4EF2LMNA | |
| D-Captopril SCHEMBL2444053 | 0.98 | ACE (1.00) | ACERENKDM4EF2LMNA | |
| Captopril SCHEMBL2786691 | 0.98 | ACE (1.00) | ACERENKDM4EF2LMNA | |
| Captopril SCHEMBL4 | 0.98 | ACE (1.00) | ACERENKDM4EF2LMNA | |
| D-Captopril SCHEMBL675797 | 0.98 | ACE (1.00) | ACERENKDM4EF2LMNA | |
| D-Captopril SCHEMBL2444049 | 0.98 | ACE (1.00) | ACERENKDM4EF2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927028-B2 | Pharmaceutical composition containing coated, floating particles | JAGOTEC AG (CH) | 2015-01-06 | — | — | US | claimed |
| EP-1382331-B1 | A pharmaceutical tablet characterized by showing a high volume increase when coming into contact with biological fluids | JAGOTEC AG (CH) | 2011-10-26 | — | — | EP | claimed |
| US-20080317841-A1 | Pharmaceutical Composition Containing Coated, Floating Particles | JAGOTEC AG (CH) | 2008-12-25 | — | — | US | claimed |
| US-20080020041-A1 | Enteric Coated Compositions that Release Active Ingredient(s) in Gastric Fluid and Intestinal Fluid | STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF OREGON STATE UNIVERSITY | 2008-01-24 | — | — | US | claimed |
| EP-1835893-A1 | PHARMACEUTICAL COMPOSITION CONTAINING COATED, FLOATING PARTICLES | Jagotec AG (CH) | 2007-09-26 | — | — | EP | claimed |
| EP-1811975-A2 | ENTERIC COATED COMPOSITIONS THAT RELEASE ACTIVE INGREDIENT(S) IN GASTRIC FLUID AND INTESTINAL FLUID | The State of Oregon Acting by and (US) | 2007-08-01 | — | — | EP | claimed |
| WO-2006063858-A1 | PHARMACEUTICAL COMPOSITION CONTAINING COATED, FLOATING PARTICLES | JAGOTEC AG (CH) | 2006-06-22 | — | — | WO | claimed |
| WO-2006044202-A2 | ENTERIC COATED COMPOSITIONS THAT RELEASE ACTIVE INGREDIENT(S) IN GASTRIC FLUID AND INTESTINAL FLUID | STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF OREGON STATE UNIVERSITY (US) | 2006-04-27 | — | — | WO | claimed |
| WO-2005011737-A2 | PHARMACEUTICAL COMBINATIONS AND FORMULATIONS WITH IMPROVED STABILITY | CIPLA LIMITED (IN) | 2005-02-10 | — | — | WO | claimed |
| EP-0795324-B1 | A pharmaceutical tablet characterized by showing a high volume increase when coming into contact with biological fluids | JAGOTEC AG (CH) | 2004-04-21 | — | — | EP | claimed |
| EP-1382331-A1 | A pharmaceutical tablet characterized by a showing high volume increase when coming into contact with biological fluids | JAGOTEC AG (CH) | 2004-01-21 | — | — | EP | claimed |
| US-5780057-A | Pharmaceutical tablet characterized by a showing high volume increase when coming into contact with biological fluids | JAGOTEC AG (CH) | 1998-07-14 | — | — | US | claimed |
| EP-0795324-A2 | A pharmaceutical tablet characterized by a showing high volume increase when coming into contact with biological fluids | JAGOTEC AG (CH) | 1997-09-17 | — | — | EP | claimed |
| CN-115040532-A | Treatment of cancer using TLR9 agonists and checkpoint inhibitors | 伊黛拉制药有限公司 | 2022-09-13 | — | — | CN | disclosed |
| CN-110325178-B | Method for producing preparation with improved content uniformity | 盐野义制药株式会社 | 2022-05-13 | — | — | CN | disclosed |
| US-11135217-B2 | Manufacturing process of formulation having improved content uniformity | SHIONOGI & CO., LTD. (JP) | 2021-10-05 | — | — | US | disclosed |
| WO-2003051333-A1 | REVERSE-MICELLAR DELIVERY SYSTEM FOR CONTROLLED TRANSPORTATION AND ENHANCED ABSORPTION OF AGENTS | MACGREGOR ALEXANDER (CA) | 2003-06-26 | — | — | WO | disclosed |
| US-20030113366-A1 | Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents | MACGREGOR ALEXANDER (CA) | 2003-06-19 | — | — | US | disclosed |
| US-5780057-A | Pharmaceutical tablet characterized by a showing high volume increase when coming into contact with biological fluids | JAGOTEC AG (CH) | 1998-07-14 | — | — | US | disclosed |
| EP-0795324-A2 | A pharmaceutical tablet characterized by a showing high volume increase when coming into contact with biological fluids | JAGOTEC AG (CH) | 1997-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11135217-B2 | Manufacturing process of formulation having improved content uniformity | FIP1L1, SAMM50, SRI | ACE 1976/4885REN 2759/4885KDM4E 1864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.